Former Chief Executive Officer · MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Paul Friedman

A named executive officer of MADRIGAL PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$9,563,286

Salary $498,846Stock awards $7,999,867

FY2022: $5,395,385

2nd of 7 named executive officers at Madrigal Pharmaceuticals by FY2023 total.

7 named officers on file for MADRIGAL PHARMACEUTICALS, FY2023

Paul Friedman’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • MDGL’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how MADRIGAL PHARMACEUTICALS’s whole pay program stands against its peers

  • MADRIGAL PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MDGL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Paul Friedman’s full pay file as a PDF — free

More than this page: up to 10 years of Paul’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Paul Friedman compensation by year

MADRIGAL PHARMACEUTICALS Summary Compensation Table · all 8 fiscal years held
In US dollars, as MADRIGAL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$175,898$400,000$416,666$584,000$603,500$627,650$658,021$498,846
Bonus$0$0$0$0$0$0$0$0
Stock awards$1,447,060$0$0$0$0$0$0$7,999,867
Option awards$2,278,545$629,424$4,907,500$5,122,000$3,468,500$4,267,500$4,239,900$0
Non-equity incentive$84,000$335,000$304,500$387,192$463,446$423,239$497,464$0
Pension and deferred compensation$0$0$0$0$0$0$0$0
All other$465$558$0$0$0$0$0$1,064,573
Total$3,985,968$1,364,982$5,628,666$6,093,192$4,535,446$5,318,389$5,395,385$9,563,286

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 29, 2024, accession 0001193125-24-122657, and prior-year filings. Open the filing on EDGAR.

How this page was built: the MADRIGAL PHARMACEUTICALS, INC. filed document, accession 0001193125-24-122657. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$4.0M
$1.4M
$5.6M
$6.1M
$4.5M
$5.3M
$5.4M
$9.6M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU26,668$6,170,442—
Option39,375—$87.09
Option15,625—$117.55
Option3,125—$91.79

Per the Outstanding Equity Awards at Fiscal Year-End table in MADRIGAL PHARMACEUTICALS, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

97 Form 4 lines since the FY2023 proxy (filed April 29, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-09Sale10b5-12,432$525.05194,222
2026-01-09Exercise or conversion10b5-124,520$15.80211,684
2026-01-09Sale10b5-11,345$514.68207,765
2026-01-09Sale10b5-12,450$517.86202,553
2026-01-09Sale10b5-1681$521.03199,663
2026-01-09Sale10b5-1840$521.98198,823
2026-01-09Sale10b5-1970$523.00197,853
2026-01-09Sale10b5-11,199$524.10196,654

The 8 most recent of 97 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

MADRIGAL PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Bill SiboldPresident and Chief Executive Officer$32,268,400
Paul Friedman · this pageFormer Chief Executive Officer$9,563,286
Remy SukhijaFormer Senior Vice President, Chief Commercial Officer$7,362,378
Rebecca TaubPresident, Research & Development and Chief Medical Officer$6,928,008
Brian LynchFormer Senior Vice President and General Counsel$5,266,584
Alex HowarthFormer Senior Vice President and Chief Financial Officer$5,262,023
Carole HuntsmanChief Commercial Officer$3,142,354

Board service

MADRIGAL PHARMACEUTICALS board · FY2023–FY2025
Director compensation in US dollars, as MADRIGAL PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$59,750$409,397$0$0$469,147
FY2024$59,000$399,887—$50,000$508,887
FY2023$10,625$0—$0$10,625

Each year as the company reported it in MADRIGAL PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: MADRIGAL PHARMACEUTICALS pays directors a $50,000 cash retainer and $400,000 in RSUs and stock options. As stated in MADRIGAL PHARMACEUTICALS's FY2025 proxy.

Committees

Science and Technology

The full MADRIGAL PHARMACEUTICALS compensation record

free company brief

This page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the MADRIGAL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Paul Friedman's compensation dossier · One-time report. No refunds.